€6m · Series A · Healthtech · Óbidos, Portugal
Portuguese digital health company Hope Care has closed €6m in entirely new Series A capital. Iberis Capital led the round, with participation from Vieira de Matos – VDM Capital and existing shareholder Buenavista Equity Partners. The financing will support European expansion, stronger commercial and operational capacity, and more remote patient monitoring deployments.
Hope Care develops OpMA, the commercial name for HCAlert V1.3, a Class IIb software medical device under the EU Medical Device Regulation. The platform combines readings from medical devices, patient-reported outcomes and clinical workflows so healthcare organisations can run centralised telehealth and remote-care programmes across chronic conditions. Hope Care says it is already delivering programmes in Portugal and France, with a project underway in Switzerland.
From home monitoring to health-system infrastructure
The customer is not simply buying a patient app. Hope Care is selling the operating layer behind hospital-led care outside the hospital: a clinical dashboard, device integrations, alerts and configurable pathways that let teams monitor patients between appointments. Its device description explains that HCAlert receives health data from multiple suppliers and creates alerts according to defined clinical programmes or protocols.
That position creates a demanding but defensible sales motion. Hospitals need evidence that the software can fit clinical processes, pass medical-device scrutiny and support real interventions, not just collect data. Hope Care says its technology is used by 15 Local Health Units covering about 45% of registered users in Portugal's SNS, alongside Madeira and the Azores. It also reported first-half 2026 sales at 2.5 times the prior-year level. These are company-reported figures, but they show the installed base the new investors are backing.
Expansion depends on deployment
The next phase is already tied to named markets. Hope Care established a German subsidiary at Medical Valley in Erlangen and said its first German deployment was scheduled for October 2026. It also reported work toward a Romanian presence and a programme with the French hospital group GHT Saône-et-Loire Bresse Morvan. Those milestones matter more than a generic expansion promise because regulated health software only creates value when procurement, integration and clinical adoption turn into operating programmes.
The Series A therefore funds an execution problem as much as a product roadmap. Hope Care must adapt OpMA to different health-system workflows while keeping its regulated core, interoperability and evidence base coherent. If it can repeat the institutional model built in Portugal, the platform could become shared infrastructure for outpatient monitoring; if deployments remain highly bespoke, commercial growth may continue to demand substantial implementation capacity.
Sources checked:
Hope Care funding announcement · Hope Care · Device description · Regulatory information · Hope Care contacts · Tech.eu Funding Explorer
